Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019

Authors
Raf Bisschops1, James E. East2,3, Cesare Hassan4, Yark Hazewinkel5, Michal F. Kamiński6,7,8, Helmut Neumann9, Maria Pellissier9,10, Giulio Antonelli11, Marco Bustamante Balen13,14, Emmanuel Coron15, Georges Cortas16, Marietta Iacucci17, Mori Yuichi18, Gaius Longcroft-Wheaton19, Nastazja Pilonis20,21, Ignasi Puig22,23, Jeanin E. van Hooft5, Evelien Dekker5

Institutions
1 University Hospitals Leuven, Department of Gastroenterology and Hepatology, TARGID, KU Leuven, Belgium
2 Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford, UK
3 Oxford National Institute for Health Research Biomedical Research Centre, Oxford, UK
4 Digestive Endoscopy Unit, Nuovo Regina Margherita Hospital, Rome, Italy
5 Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
6 Department of Gastroenterological Oncology, the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
7 Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
8 Institute of Health and Society, University of Oslo, Oslo, Norway
9 Department of Medicine I, University Medical Center Mainz, Mainz, Germany
10 Department of Gastroenterology, Institut Clinic de Malalties Digestives i Metabòliques, Hospital Clinic de Barcelona, Barcelona, Spain
11 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
12 Endoscopy Unit, Sant’Andrea University Hospital, “Sapienza” University of Rome, Rome, Italy
13 Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic University Hospital, Valencia, Spain
14 Gastrointestinal Endoscopy Research Group, La Fe Health Research Institute, Valencia, Spain
15 CHU Nantes, Université Nantes, Institut des Maladies de l’Appareil Digestif (IMAD), Nantes, France
16 Division of Gastroenterology, University of Balamand Faculty of Medicine, St. George Hospital University Medical Center, Beirut, Lebanon
17 Institute of Translational Medicine, Institute of Immunology and Immunotherapy and NIHR Biomedical Research Centre, University of Birmingham and University Hospitals, Birmingham NHS Foundation Trust, UK
18 Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
19 Portsmouth Hospitals NHS Trust, Cosham, Portsmouth, UK
20 Department of Gastroenterological Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
21 Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
22 Digestive Diseases Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain
23 Department of Medicine, Facultat de Ciències de la Salut, Universitat de Vic–Universitat Central de Catalunya (UVic-UCC), Manresa, Spain

Bibliography
DOI https://doi.org/10.1055/a-1031-7657
Published online: 11.11.2019 | Endoscopy 2019; 51: 1155–1179
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0013-726X

Corresponding author
Raf Bisschops, MD PhD, University Hospitals Leuven, Targid, Gastroenterology and Hepatology, 49 Herstraat, Leuven 3000, Belgium
Fax: +32344419
raf.bisschops@uzleuven.be
MAIN RECOMMENDATIONS

1 ESGE suggests that high definition endoscopy, and dye or virtual chromoendoscopy, as well as add-on devices, can be used in average risk patients to increase the endoscopist’s adenoma detection rate. However, their routine use must be balanced against costs and practical considerations. Weak recommendation, high quality evidence.

2 ESGE recommends the routine use of high definition systems in individuals with Lynch syndrome. Strong recommendation, high quality evidence.

3 ESGE recommends the routine use, with targeted biopsies, of dye-based pancolonic chromoendoscopy or virtual chromoendoscopy for neoplasia surveillance in patients with long-standing colitis. Strong recommendation, moderate quality evidence.

4 ESGE suggests that virtual chromoendoscopy and dye-based chromoendoscopy can be used, under strictly controlled conditions, for real-time optical diagnosis of diminutive (≤ 5 mm) colorectal polyps and can replace histopathological diagnosis. The optical diagnosis has to be reported using validated scales, must be adequately photodocumented, and can be performed only by experienced endoscopists who are adequately trained, as defined in the ESGE curriculum, and audited. Weak recommendation, high quality evidence.

5 ESGE recommends the use of high definition white-light endoscopy in combination with (virtual) chromoendoscopy to predict the presence and depth of any submucosal invasion in nonpedunculated colorectal polyps prior to any treatment. Strong recommendation, moderate quality evidence.

6 ESGE recommends the use of virtual or dye-based chromoendoscopy in addition to white-light endoscopy for the detection of residual neoplasia at a piecemeal polypectomy scar site. Strong recommendation, moderate quality evidence.

7 ESGE suggests the possible incorporation of computer-aided diagnosis (detection and characterization of lesions) to colonoscopy, if acceptable and reproducible accuracy for colorectal neoplasia is demonstrated in high quality multicenter in vivo clinical studies. Possible significant risks with implementation, specifically endoscopist deskilling and over-reliance on artificial intelligence, unrepresentative training datasets, and hacking, need to be considered. Weak recommendation, low quality evidence.

ABBREVIATIONS

ADR adenoma detection rate
AFI autofluorescence imaging endoscopy
AI artificial intelligence
ASGE American Society for Gastrointestinal Endoscopy
BLI blue light imaging
CE chromoendoscopy
CI confidence interval
CRC colorectal cancer
EMR endoscopic mucosal resection
ESD endoscopic submucosal dissection
ETMI endoscopic trimodal imaging
FACILE Frankfurt Advanced Chromoendoscopic IBD Lesions
FAP familial adenomatous polyposis
FICE flexible spectral imaging color enhancement
FTRD full thickness resection device
GRADE Grading of Recommendations Assessment, Development and Evaluation
HD-WLE high definition white-light endoscopy
HGD high grade dysplasia
I-SCAN i-SCAN digital contrast
JNET Japan NBI Expert Team
LCI linked color imaging
LGD low grade dysplasia
LST laterally spreading tumor
MB-MMX methylene blue formulation
NBI narrow band imaging
NICE NBI International Colorectal Endoscopic
NG nongranular
PDR polyp detection rate
PICO patient, intervention, comparator, outcome
RCT randomized controlled trial
SD-WLE standard definition white-light endoscopy
SPS serrated polyposis syndrome
SSL sessile serrated lesion
UC ulcerative colitis
WASP Workgroup serrAted polypS and Polyposis
WLE white-light endoscopy
SOURCE AND SCOPE
This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It is a revision of the previously published 2014 Guideline addressing the role of advanced endoscopic imaging for detection and differentiation of colorectal neoplasia.

Introduction
Colonoscopy is the key examination technique in colorectal cancer (CRC) screening programs for detection and treatment of early precursor lesions and timely diagnosis of colorectal cancer [1, 2]. The quality of colonoscopy, which depends on both bowel preparation and examination technique, is the main determining factor that drives the protective effect of this invasive examination in decreasing the societal disease burden [3–5].

Over the last 15 years, several new techniques to improve polyp detection and characterization have been developed and studied [6]. For all these techniques, the possible financial burden, learning curve, and additional cost need to be balanced against the potential benefit. In general, there is a potential bias in the available literature given that it is impossible to blind the endoscopist to the technique that is being studied. Therefore, even the setting of a fully randomized trial, there is always a potential bias in favor of any technique that may affect the performance of the endoscopists, even subconsciously.

This update of the previously published Guideline [7] aims to put into perspective the new evidence that has become available over the last 5 years, and to provide statements on the possible role of advanced techniques in polyp detection or characterization in the average-risk and high-risk populations. The potential role of artificial intelligence (AI) in the detection and characterization of colorectal lesions, including possible hazards of its implementation, has been addressed for the first time.

With regard to training, in optical diagnosis of diminutive polyps, detection of colitis-associated neoplasia, and prediction of invasion with larger polyps, we refer to the standardized ESGE training curriculum. Although this is a work in progress, we anticipate that the curriculum will be available in 2020 and want to include this defined standard in the Guideline as a prerequisite for obtaining cognitive chromoendoscopy (CE) skills for lesion characterization and detection.

Methods
The ESGE commissioned this Guideline (Guideline Committee chair, J.v.H.) and appointed a guideline leader (R.B.), who invited the listed authors to participate in the project development. The key questions were prepared by the coordinating team (R.B., E.D., J.E.E., M.P., M.K., C.H., H.N.) and were then approved by the other members. The coordinating team established task force subgroups, based on the statements of the previous 2014 Guideline [7], each with its own leader, and divided the key topics among those task forces (Appendix 1s; see online-only Supplementary Material) with a specific focus on the update of literature and revision of the statements.

The Guideline was developed during September 2018 and June 2019. The work included telephone conferences, a face-to-face meeting, and online discussions, and additional Delphi voting if necessary. In addition to the five task forces of the previous Guideline, we included a sixth task force to address the role of artificial intelligence (AI) in the detection and characterization of colorectal polyps. The task forces conducted a literature search related to the following techniques: high definition endoscopy, chromoendoscopy or dye-based endoscopy, virtual chromoendoscopy (narrow band imaging [NBI], i-SCAN digital contrast [i-SCAN], flexible spectral imaging color enhancement [FICE], and blue light imaging [BLI]), autofluorescence imaging (AFI) endoscopy, and add-on devices. Techniques that have been under development or without clear clinical implementation since the publication of the previous Guideline were not included (i.e., confocal endomicroscopy, endocytoscopy, optical coherence tomography). Key questions were formulated using patient, intervention, comparator, outcome (PICO) methodology [8].

The literature search was conducted through Medline (via Pubmed) and the Cochrane Central Register of Controlled Trials up to June 2019. New evidence on each key question was summarized in tables, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [9]. Grading depends on the balance between the benefits and risk or burden of any health intervention (Appendix 2s). Further details on guideline development have been previously reported [10].

The results of the search were presented to all group members during a meeting in Prague on April 1st 2019. Subsequently, drafts were made by each task force chair and distributed between the task force members for revision and online discussion. Statements were created by consensus, or by Delphi voting of two rounds for task force 2.

In July 2019, a draft prepared by R.B. and all the task force chairs was sent to all group members. After agreement of all members had been obtained, the manuscript was reviewed by two external reviewers, Prof. Brian Saunders and Dr. David Tate. It was then sent for further comments to the ESGE national societies and individual members. It was then submitted to the journal Endoscopy for publication. The final revised manuscript was agreed upon by all the authors.

This Guideline was issued in 2019 and will be considered for update in 2024. Any interim updates will be noted on the ESGE website: http://www.esge.com/esge-guidelines.html.

Evidence and statements
Evidence statements are compared to those of the previous 2014 Guideline [7]. The 2014 statements are shown in italic. The statements are grouped according to the different task force topics.
Detection of colorectal neoplasia in the average risk population

**RECOMMENDATION**

2014 statements:
ESGE suggests the routine use of high definition white-light endoscopy systems for detecting colorectal neoplasia in average risk populations (weak recommendation, moderate quality evidence).

ESGE does not recommend routine use of virtual pancolonic chromoendoscopy, AFI, or add-on devices for detecting colorectal neoplasia in average risk populations (strong recommendation, high quality evidence).

2019 statement:

ESGE suggests that high definition endoscopy, and dye or virtual chromoendoscopy, as well as add-on devices, can be used in average risk patients to increase the endoscopist’s adenoma detection rate. However, their routine use must be balanced against costs and practical considerations.

Weak recommendation, high quality evidence.

The term “average risk population” refers to patients undergoing screening colonoscopy outside the setting of colitis or hereditary syndromes. Colorectal cancer screening is performed on a large scale in Europe, and therefore a small increase in adenoma detection may have a significant effect on the health care outcome of colorectal cancer [11]. Nonetheless, because of the widespread use of colonoscopy for colorectal cancer screening, the cost and practicality of advanced imaging techniques or add-on devices must be taken into consideration to avoid excessive financial or organizational burdens.

**High definition endoscopy**

A 2011 meta-analysis of five studies including 4422 average risk patients showed a 3.5% (95% confidence interval [CI] 0.9%–6.1%) incremental yield from high definition white-light endoscopy (HD-WLE) over standard definition white-light endoscopy (SD-WLE) for the detection of patients with at least one adenoma [12]. There were no differences between HD-WLE and SD-WLE for high risk adenomas. We postulate that the difference in the fields of view of the endoscopes that were used is unlikely to account for the increased yield observed with HD-WLE, because three randomized controlled trials (RCTs) from two centers found no significant difference in polyp detection rates between SD-WLE endoscopies with 140° and 170° fields of view [13–15].

Also in a two-center RCT [16] published after the meta-analysis, the proportion of participants in whom adenomas were detected with HD-WLE was higher as compared with SD-WLE (45.7% vs. 38.6%, \(P = 0.166\)). The difference was significant for patients with flat adenomas (9.5% vs. 2.4%, \(P = 0.003\)) and right-sided adenomas (34.0% vs. 19.0%, \(P = 0.001\)).

A recent RCT [17] comparing HD-WLE with SD-WLE in 1855 patients has shown a significant increase in detection of sessile serrated lesions, also precursors for CRC (8.2% vs. 3.8%), as well as adenocarcinomas (2.6% vs. 0.5%). However, in this study no difference in adenoma detection rate (ADR) or polyp detection rate (PDR) was seen.

Two recent multicenter RCTs [18, 19] have postulated that two generations of improvements in colonoscopes are necessary to significantly increase ADR. The two RCTs compared the latest generation HD-WLE colonoscopes from one company (Olympus 190C) against standard definition next-to-last generation colonoscopes (Olympus 160C) in both a hospital [18] and in a private practice [19] setting. Results from the two trials were not fully concordant. In the hospital setting, a significant decrease in adenoma miss rates was found with high definition colonoscopes (16.6%, 95% CI 13.0%–20.1% vs. 30.2%, 95% CI 25.9%–34.6%; \(P < 0.001\)) as well as a significant increase in ADR (43.8% vs. 36.5%, \(P = 0.03\)) [18]. In the private practice setting [19] however, the ADR difference in favor of the latest-generation colonoscope did not reach statistical significance (32% vs. 28%, \(P = 0.10\)). The detection of diminutive polyps (<5 mm) was significantly increased (22.5% vs. 15.6%, \(P < 0.001\)) for HD-WLE, as well as the adenoma per patient rate (all adenomas/all patients: 0.57 vs. 0.47, \(P < 0.001\)). Details of these RCTs are available in Table 1s (see Appendix 3s; online-only Supplementary Material).

The cost–effectiveness of using HD-WLE in routine practice was not studied. High definition colonoscopes are available from all major manufacturers.

Based on the above results with moderate-to-high quality evidence, we can conclude that high definition systems may be of benefit to improve polyp and adenoma detection, although trial results are not entirely consistent.

**Virtual chromoendoscopy**

**Narrow band imaging (NBI)**

Four meta-analyses and one Cochrane systematic review of RCTs compared detection of colorectal lesions in average risk populations using WLE and NBI [20–24]. When considering HD-WLE versus HD-NBI, none of these showed a significant difference in adenoma detection rate between the two technologies. HD-NBI showed a small increase in detection rate when compared to SD-WLE only.

A very recent meta-analysis [25] comprised data of 4491 individual patients from 11 RCTs. In this study, high definition NBI (HD-NBI) showed a significant increase in unadjusted odds ratio for adenoma detection compared to HD-WLE (OR 1.14, 95% CI 1.01–1.29, \(P = 0.04\); ADRs, HD-WLE 42.3% vs. HD-NBI 45.2%). When subanalyses were performed, NBI showed an increased detection only when preparation was best (compared to average). Moreover, it was only second-generation NBI, with a brighter light, that significantly increased ADR, and not the first-generation (second-generation NBI OR 1.28, 95% CI 1.05–1.56, \(P = 0.02\)).

We can therefore conclude that the additional value of NBI in polyp detection is rather marginal, taking into consideration...
the marginal significance in the meta-analysis. The introduction of better imaging quality with HD systems has probably a more important role.

**i-SCAN digital contrast (i-SCAN), flexible spectral imaging color enhancement (FICE), blue light imaging (BLI), and linked color imaging (LCI)**

One meta-analysis, published in 2014 and including 5 studies with 3032 patients [23], compared HD-FICE and HD-i-SCAN versus HD-WLE in the detection of adenomas and found no additional detection with these advanced techniques (RR 1.09, 95%CI 0.97 – 1.23).

An RCT [26] published after the meta-analysis showed a favorable result for i-SCAN technology, with a significantly higher ADR in the i-SCAN group compared to the HD-WLE colonoscopy group (47.2% vs. 37.7%, *P* = 0.01). This result, however, was mainly due to an increased detection rate of diminutive, flat, and right-sided adenomas.

Data on BLI and LCI for the detection of colorectal lesions are preliminary. Recent RCTs on LCI showed an increased per-patient ADR compared to HD-WLE (37% vs. 28%) [27], as well as a reduction in the miss rate in the right colon [28]. The single recent RCT on BLI [29] showed an increased mean adenoma per patient rate (mean ± standard deviation [SD] 1.27±1.73 vs. 1.01±1.36, *P* = 0.008), but no increase in ADR or PDR compared to HD-WLE.

Details of the most important studies are available in **Table 2s**.

In conclusion, data on advanced imaging with these techniques is scarce and the beneficial effect in terms of incremental polyp detection seems to be clinically marginal.

**Auto fluorescence imaging (AFI) endoscopy**

One meta-analysis published in 2015 [30], including six RCTs and 1199 patients, evaluated AFI for the detection of colorectal neoplasia in average risk patients, and showed no significant difference between AFI and WLE in ADR or PDR (ADR, OR 1.01, 95%CI 0.74 – 1.37, *P* = 0.96; PDR, OR 0.86, 95%CI 0.57 – 1.30, *P* = 0.71), with no significant heterogeneity among the studies (*P* = 0.67, *I*² = 0).

One recently published RCT [31] focused on the role of updated AFI in the detection of flat lesions and showed a significant increase in the detection of right-sided flat lesions (adenomas and carcinoma, not sessile serrated polyps) (0.87, 95%CI 0.78 – 0.97 vs 0.53, 95%CI 0.46 – 0.61), but no increase in overall ADR or PDR.

Details of these two studies are available in **Table 3s**.

Based on the findings of the meta-analysis, there seems to be no major additional value of AFI for polyp detection in the average risk population. In addition, the system is not commercially available.

**Add-on devices**

In 2018, two network meta-analyses investigating the efficacy of add-on devices to improve ADR (cap, Endocuff, Endorings) were published [32, 33] (**Table 4s**).

One network meta-analysis, including 25 RCTs and 16 103 patients [32], showed an overall slight increase in ADR for add-on devices compared to standard colonoscopy (39.3% vs. 35.1%; relative risk [RR] 1.13, 95%CI 1.03 – 1.23; *P* = 0.007). When individual devices were considered, both Endocuff versus HD-WLE and Endorings versus standard colonoscopy showed a small but significant improvement in ADR; these however would be of benefit mostly for already high-performing endoscopists. The use of a short transparent cap at the tip of the endoscope resulted in a statistically insignificant increase in ADR compared to HD-WLE (37% vs. 34.3%; RR 1.07, 95%CI 0.96 – 1.19; *P* = 0.19). However, the considerable heterogeneity (*I*² = 89%) should lead to cautious interpretation of these results. Subgroup analysis revealed a substantial increase of ADR and PDR of lesions ≤ 5 mm (RR 1.53, 95%CI 1.13 – 1.71, RR 1.38, 95%CI 1.10 – 1.43, respectively).

The second network meta-analysis [33] included 10 studies reporting on 6047 patients and showed, in contrast to the first, an overall increase in ADR for Endocuff in comparison to HD-WLE (OR 1.36, 95%CI 1.12 – 1.60; *P* < 0.001), but when a subgroup analysis was performed, this was only significant in low-performing endoscopists (for ADR <25%: OR 1.85, 95%CI 1.35 – 2.53, *P* = 0.0001).

Most RCTs do not report cost-effectiveness data and this aspect has not yet been evaluated systematically.

Based on the available data, the evidence for general use of add-on devices is rather weak and cost-effectiveness has never been well assessed. It might however have a role in helping low-performers to reach the important ADR threshold of 25% [4].

**Dye-based chromoendoscopy (CE)**

A recently updated Cochrane systematic review of 2016 [34] analyzed 7 RCTs (total 2727 patients) that assessed the role of dye-based CE in detecting colorectal lesions outside the setting of polyposis or colitis. Pancolonic CE significantly increased the number of patients with at least one polyp detected (OR 1.87, 95%CI 1.51 – 2.30) and of those with at least one neoplastic polyp (adenoma or carcinoma) detected (OR 1.53, 95%CI 1.31 – 1.79). Limitations of the systematic review were the lack of blinding in the RCTs, and the significant heterogeneity observed between the studies. Indeed, quality of evidence was graded as low in this review.

Since the publication of that Cochrane systematic review, two large multicenter RCTs have been published. The first [35], including 1065 patients, showed an increase in the mean adenoma per patient rate (0.79 vs. 0.64, *P* = 0.005), but not in ADR (40.4% vs. 37.5%; OR 1.13, 95%CI 0.87 – 1.48; *P* = 0.35) or sessile serrated lesion detection rate, using routine pancolonic CE compared to HD-WLE.

A recent phase 3 multicenter RCT [36] has evaluated the role of a novel pH- and time-dependent peroral methylene blue formulation (MB-MMX) that is delivered in pills taken during the bowel preparation phase. This RCT enrolled 1205 patients undergoing screening or surveillance colonoscopy and found an increased overall ADR in the MB-MMX group compared to the placebo group (56.29 vs 47.81%; OR 1.46, 95%CI 1.09 – 1.96). The MB-MMX group showed a higher number of patients with...
adenomas ≤ 5 mm (37.11% vs. 30.90%; OR 1.36, 95%CI 1.01 – 1.83).

Details of the abovementioned studies are available in Table 5s.

We can conclude that chromoendoscopy increases ADR and PDR; however its systematic implementation may be hampered in daily practice because of practical considerations and additional costs. The use of MB-MMX may help to overcome these.

Detection of colorectal neoplasia in high risk populations with hereditary syndromes

**RECOMMENDATIONS**

**2014 statements:**

ESGE recommends the routine use of high definition pan-colonic chromoendoscopy in patients with known or suspected Lynch syndrome (conventional chromoendoscopy, NBI, i-SCAN) or serrated polyposis syndrome (conventional chromoendoscopy, NBI) (strong recommendation, low quality evidence).

ESGE does not make any recommendation for the use of advanced endoscopic imaging in patients with suspected or known familial adenomatous polyposis (FAP) including attenuated and MUTYH-associated polyposis (insufficient evidence to make a recommendation).

**2019 statements:**

ESGE recommends the routine use of high definition systems in individuals with Lynch syndrome. Strong recommendation, high quality evidence.

ESGE suggests that the use of virtual chromoendoscopy may be of benefit in individuals with Lynch syndrome undergoing colonoscopy; however its routine use must be balanced against costs, training, and other practical considerations.

Weak recommendation, moderate quality evidence.

ESGE suggests the use of high definition systems and dye-based chromoendoscopy in the diagnosis with surveillance of individuals with serrated polyposis syndrome; however routine use must be balanced against costs, training, and practical considerations.

Weak recommendation, moderate quality evidence.

ESGE does not recommend the systematic use of dye-based nor virtual chromoendoscopy for familial adenomatous polyposis (FAP), MUTYH-associated polyposis, or hamartomatous polyposis.

Strong recommendation, moderate quality evidence.

**Lynch syndrome**

Lynch syndrome is the most common cause of hereditary colorectal cancer (CRC). It is an autosomal dominant disorder caused by germline mutations in the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2, MSH6, PMS2, and EpcAM). An accelerated progression from adenoma to CRC has been described, and often the adenomas display advanced histological features (i.e., high grade dysplasia or a villous component), are frequently flat in morphology, and located in the proximal colon, compared with sporadic adenomas. An intensive surveillance strategy with annual or biennial colonoscopy starting at early ages has reduced both the incidence and mortality associated with CRC. A high detection rate for these aggressive adenomas is especially important to minimize the risk of interval CRC.

In total, seven studies comparing indigo carmine CE with WLE in patients with Lynch syndrome have been published [37–43] (Table 6s). Three single-center studies with a small number of patients in a back-to-back design showed that CE was superior to SD-WLE, with an adenoma miss rate ranging from 61% to 74% [37, 38, 41]. A recent back-to-back multicenter study, where the second pass was performed by a different endoscopist in order to minimize the second inspection bias, again showed superiority of SD-CE over SD-WLE (ADRs of 41% and 23%, respectively; adenoma miss rate 52%). Nevertheless, the study had no comparator arm, was slightly underpowered (β-risk of 26%) and the withdrawal time during CE was twice that of WLE [39]. All these results are methodologically flawed by the back-to-back design that may lead to an overestimation of the effect of CE over WLE.

There are three trials with a control arm. A study by Stoffel et al. included 54 patients in four centers [40]. After the first pass with SD-WLE, 28 patients were randomly allocated to a second pass with CE and 27 to a second pass with an intensive 20-minute inspection; no significant difference in adenoma miss rate was shown.

Very recently, two well-powered randomized, multicenter, controlled studies with a comparator arm were published. Haanstra et al. showed no differences in neoplasia detection rate between CE and WLE in 246 Lynch patients, either at baseline (27% vs. 30%, respectively; \( P = 0.56 \)) or in the 2-year follow-up colonoscopy (26% vs. 28%, respectively; \( P = 0.81 \)) [42]. This study is limited by the fact that CE was applied only proximal to the splenic flexure and that the study extended over a very long recruitment period (10 years) which may entail important variability in procedure performances and ability for detecting colorectal lesions. Rivero-Sánchez et al. performed a study with only HD endoscopes and high-detector endoscopists in 256 Lynch patients in 14 different hospitals, and showed that ADR was statistically not different between HD-CE and HD-WLE (34.4% [95%CI 26.4%–43.3%] vs. 28.1% [95%CI 21.1%–36.4%], \( P = 0.28 \)) [43]. In both trials, CE was more time-consuming and detected more clinically irrelevant lesions.

In Lynch patients, three single-center back-to-back studies were performed with high definition virtual CE, which appeared to be superior to HD-WLE for polyp detection [44, 45]. East et al. showed in a nonrandomized back-to-back study in 62 Lynch patients that during a second inspection, with NBI, additional adenomas were detected in 17/62 patients (27%). In this study, ADR increased to 26/62 (42%) after both WLE and NBI; 9/62 patients had at least one adenoma detected that was missed during the first inspection with WLE [44]. Bisschops et al. showed...
in a randomized crossover study in 61 Lynch patients that the adenoma miss rate was significantly lower when I-SCAN was used, in comparison to HD-WLE (12% vs. 62%) [45]. Both studies were conducted by a single expert endoscopist and in the second study, the ADR was relatively low for HD-WLE inspection (19%).

On the other hand, virtual CE appears to be inferior to dye-based CE in two back-to-back studies. In a German cohort study the incremental yield of CE versus SD-WLE (n = 47) and NBI (n = 62) was assessed, showing a higher detection with CE during second inspection [41]. Very recently, a study comparing NBI to CE in a back-to-back design has been published as an abstract. This multicenter French study, in 138 Lynch patients, showed an adenoma miss rate of 48% for the third generation of HD-NBI devices (Exera III, 190 series) when followed by a second pass with dye-based CE by the same endoscopist. The authors concluded that although NBI colonoscopy is less time-consuming, it cannot be recommended to replace dye-based CE in Lynch syndrome patients [46].

Finally, one study in 75 patients compared AFI with the Xillix system (XillixTechnologies Corporation, Richmond, British Columbia, Canada), to WLE in a crossover trial, showing a better detection of adenomas for AFI (92% vs. 68% for WLE) [47]. Details for the most important studies are available in Table 7.

In conclusion, evidence suggests a benefit of dye-based CE in Lynch syndrome patients at the expense of longer procedure times. However, most of the studies were performed with standard definition endoscopes, had a small and heterogeneous sample, and a nonrandomized back-to-back design that may have led to a bias in favor of dye-based CE. Recent evidence from two well-powered multicenter trials with a parallel design have shown no differences in ADR between WLE and dye-based CE [42, 43]. This possibly implies that a thorough inspection by high detector endoscopists and using high definition endoscopes might decrease the advantageous effect of dye-based CE in Lynch patients. These two RCTs are the reason for a slight discrepancy between the recommendations in this Guideline and the recently published Guideline on the management of polyposis syndromes [48], that also included dye-based CE as a suggestion. However the new evidence was not available at the time of development of that Guideline. On the other hand, two studies have reported superiority of virtual CE (NBI and I-SCAN) over WLE. Conversely, two other studies have shown that dye-based CE was superior to virtual CE. Most of these studies have methodological limitations such as back-to-back design, the second pass being performed by the same expert endoscopist, or there being a low ADR in the first pass.

Taking this into consideration, ESGE recommends at least the use of HD endoscopes in Lynch patients and suggests in addition that, in view of the evidence, advanced imaging techniques such as virtual chromoendoscopy can be useful.

Serrated polyposis syndrome (SPS)

Serrated polyposis syndrome (SPS) has emerged as the most frequent colorectal polyposis syndrome. This entity is associated with an increased risk of CRC and is often grouped with the hereditary polyposis syndromes although no underlying gene defect has been identified yet.

Although recent studies show an increase in SPS prevalence [49–51], attributed to major clinical and pathological awareness and better endoscopic diagnostic accuracy [52, 53], SPS remains an underdiagnosed entity [54]. SPS diagnosis depends directly on the capacity for detecting serrated lesions (Sls), which are often easily overlooked due to their imperceptibility [51]. In a fecal immunochemical test (FIT)-based CRC screening program, a reassessment colonoscopy within 1 year after a screening colonoscopy tripled the number of patients diagnosed with SPS. Use of CE, either dye-based or virtual, at reassessment colonoscopy was associated with a higher detection rate of serrated lesions, but not of adenomas [55].

Recently, a multicenter randomized back-to-back study evaluated the usefulness of dye-based CE with indigo carmine for the detection of colonic polyps in SPS patients under surveillance [56]. Patients were randomly assigned to a group: one received two HD-WLE examinations (n = 43) and the other received HD-WLE followed by 0.4% indigo carmine CE (n = 43). This study demonstrated a significantly higher additional polyp detection rate in the HD-CE group (0.39, 95%CI 0.27–0.51) than in the HD-WLE group (0.22, 95%CI 0.18–0.27, P < 0.001). HD-CE detected more serrated lesions than HD-WLE (40% vs. 24%, P < 0.001), more serrated lesions proximal to the sigmoid (40% vs. 21%, P < 0.001), and more > 5-mm serrated lesions proximal to the sigmoid colon. Detection of adenomas and serrated lesions > 10 mm in size did not differ significantly between groups. The additional detection rate for SSP was higher in the HD-CE group (0.29 in HD-CE vs. 0.13 in HD-WL, P = 0.059) but not statistically significant. In a multivariate logistic regression analysis, only use of HD-CE was independently associated with an increase in polyp detection throughout the colon.

The role of virtual CE (i.e., NBI) in SPS has been evaluated in two randomized crossover studies. A first single-center study including 22 patients showed that NBI had a lower polyp miss rate than high resolution WLE (10% vs. 36%); however this was not confirmed in a second multicenter study including 52 SPS patients (20% vs. 29%; P = 0.065) [57, 58]. The authors explained this contradictory result by the fact that the pilot study was performed by a single endoscopist, at a single institution and with older equipment.

A recent multicenter prospective randomized controlled trial evaluated the usefulness of Endocuff-assisted colonoscopy in SPS surveillance, showing no increase in detection of sessile serrated lesions, adenomas, or polyps overall [59].

Details of the abovementioned studies are available in Table 8.

Thus, based on the abovementioned single RCT [56], the use of dye-based CE improves polyp detection and could be considered in the surveillance of SPS patients. However, its routine use must be balanced against practical considerations.
Detection and differentiation of colorectal neoplasia in inflammatory bowel disease (IBD)

Patients with long-standing or extensive ulcerative colitis (UC) or Crohn’s disease are at an increased risk of developing CRC compared to the average risk population. Accordingly, regular and extensive surveillance colonoscopies are recommended [60, 61]. In this context, advanced endoscopic imaging may be of benefit by (i) increasing the neoplasia detection rate; (ii) improving the differentiation of lesions (colitis-associated neoplasia, sporadic neoplasia, and non-neoplastic lesions); and (iii) reducing the number of unnecessary biopsies.

RECOMMENDATIONS

2014 statements:
ESGE recommends the routine use of 0.1% methylene blue or 0.1%–0.5% indigo carmine pancolonic chromoendoscopy with targeted biopsies for neoplasia surveillance in patients with long-standing colitis. In appropriately trained hands, in the situation of quiescent disease activity and adequate bowel preparation, nontargeted four-quadrant biopsies can be abandoned (strong recommendation, high-quality evidence).

ESGE found insufficient evidence to recommend for or against the use of virtual chromoendoscopy or autofluorescence imaging (AFI) for the detection of colorectal neoplasia in inflammatory bowel disease (insufficient evidence to make a recommendation).

2019 statements:
ESGE recommends the routine use of dye-based pancolonic chromoendoscopy or virtual chromoendoscopy with targeted biopsies for neoplasia surveillance in patients with long-standing colitis, in the situation of quiescent disease activity and adequate bowel preparation. Strong recommendation, moderate quality evidence.

ESGE recommends that after proper training in colonoscopy has been obtained, as defined in the ESGE curriculum, in the situation of quiescent disease activity and adequate bowel preparation, nontargeted four-quadrant biopsies can be abandoned. Strong recommendation, high quality evidence.

ESGE suggests that in the case of high risk patients with a personal history of colonic neoplasia, tubular-appearing colon, strictures, or primary sclerosing cholangitis, chromoendoscopy-targeted biopsies can be combined with four-quadrant nontargeted biopsies every 10 cm in the colon. Weak recommendation, low quality evidence.

In general, surveillance of long-standing colitis can only be accurately performed in the absence of disease activity and with an adequate bowel preparation. Indeed, all the imaging studies mentioned below only apply to patients with long-standing colitis undergoing surveillance in the setting of quiescent disease activity and adequate bowel preparation. The use of dye-based or virtual CE is technically cumbersome in the presence of active colitis, multiple inflammatory or post-inflammatory polyps, or poor bowel preparation.

SD-WLE or HD-WLE versus dye-based CE

Overall, in eight prospective studies comparing dye-based CE with SD-WLE, the former consistently increased the proportion of patients found with dysplasia by a factor of 2.08–3.26 [62–66]. A meta-analysis showed a pooled incremental yield of CE with random biopsies over SD-WLE with random biopsies for the detection of patients with neoplasia of 7% (95% CI 3.2%–11.3%). Moreover, the difference in proportion of lesions detected by targeted biopsies only was 44% (95% CI 28.6%–59.1%) in favor of dye-based CE [64]. This finding has been confirmed by a new retrospective cohort study including 78 patients with ulcerative colitis [67] in which CE visualized dysplastic lesions in 50 patients, including 34 new lesions not visualized on the index SD-WLE examination. A prospective longitudinal study included 55 patients with ulcerative colitis and identified 44 dysplastic lesions in 24 patients: 6 were detected by random biopsy, 11 by WLE, and 27 by CE [68]. CE and targeted WLE were more likely than random biopsies to detect dysplasia, and CE was superior to SD-WLE (OR 2.4, 95% CI 1.4–4.0). One retrospective cohort study including 2242 colonoscopies demonstrated equal dysplasia detection rates for CE and WLE with random biopsies (11% vs. 10%, P = 0.80) [69].

Most recently CE has been evaluated for neoplasia detection and characterization in long-standing colitis in a more real-life setting than that of a randomized controlled trial with only expert endoscopists [70]. In this multicenter prospective cohort study including 350 patients, 41.5% of colonoscopies were performed with standard definition endoscopes. The overall dysplasia miss rate for combined HD-WLE and SD-WLE was 40/94 (57.4% incremental yield for CE). The CE incremental detection yield for dysplasia was comparable between standard definition and high definition (51.5% vs. 52.3%, P = 0.30) and statistically not different between expert and nonexpert endoscopists (18.5% vs. 13.1%, P = 0.2).

Although this last study did not show a difference between SD-CE and HD-CE detection of neoplasia, the additional value of high definition endoscopy in detecting ulcerative colitis-related neoplasia has become clearer more recently, and seems to indicate that CE increases detection only when standard definition endoscopy is used as opposed to high definition. A recent meta-analysis of 10 studies (494 patients) compared dye-based CE with SD-WLE and HD-WLE [71]. Of these 6 were RCTs (3 on SD-WLE and 3 on HD-WLE). The proportion of patients diagnosed with dysplasia using CE was 17% as compared with 11% for WLE. When analyzed separately, CE was more effective at identifying dysplasia than SD-WLE (RR 2.12, 95% CI 1.15–3.91); however CE was not more effective as compared with HD-WLE (RR 1.36, 95% CI, 0.84–2.18). Based on this meta-analysis, non-RCTs demonstrated a benefit of CE over SD-WLE and HD-WLE, whereas RCTs showed a small benefit of CE over SD-WLE, but not over HD-WLE. In addition, two other meta-
analyses comparing different advanced techniques point in the same direction. One recent systematic review comparing CE to other techniques (SD-WLE, HD-WLE, HD-NBI, or HD-I-SCAN), included 10 randomized trials with 1500 participants [72]. CE was associated with higher detection of patients with dysplasia as compared with other techniques. However, subgroup analyses confirmed this effect only in comparison with SD-WLE (RR 2.12, 95% CI 1.15–3.91). These findings have been confirmed by another network meta-analysis including only 8 parallel-group RCTs with 924 patients [73] and comparing HD-WLE, SD-WLE, SD-CE, HD-CE, and HD-NBI for detection of neoplasia in long-standing colitis. The network analysis did not find any single technique to be statistically superior. CE was probably more effective than SD-WLE for detecting any dysplasia (OR 2.37, 95% CI 0.81–6.94). Finally, a recent prospective RCT compared HD-WLE alone (n = 90) with high definition dye-based CE (n = 90), and virtual CE with I-SCAN (n = 90) for detection of neoplastic lesions during IBD surveillance colonoscopy [74]. The HD-WLE neoplasia detection rate (25.5%) was noninferior either to dye-based (24.4%) or to virtual CE (15.5%) for detection of all neoplastic lesions (P = 0.91).

Details of the abovementioned studies with SD endoscopy and HD endoscopy are available in Tables 9s and 10s.

Limitations of dye-based CE in the context of long-standing colitis surveillance need to be mentioned. There is no proof that better detection of neoplasia by CE results in the reduction of CRC mortality or decreased risk of interval CRC. Data on cost-effectiveness are also limited; however a reduction in the number of colonoscopies and histological samples could be achieved by risk stratification [75]. One study assessed the cost-effectiveness of CE in comparison with WLE or no endoscopy for CRC surveillance in patients with ulcerative colitis, using a decision-analytic state-transition (Markov) model with a Monte Carlo simulation [76]. CE was found to be more effective and less expensive than WLE at all surveillance intervals. However, compared with no surveillance, CE was cost-effective only at 7-year surveillance intervals, with an incremental cost-effectiveness ratio of $77,176. At sensitivity levels of >0.23 for dysplasia detection and cost <$2200, CE was the most cost-effective strategy, regardless of the level of sensitivity of WLE. The estimated population lifetime risk of developing CRC ranged from 2.5% (annual CE) to 5.9% (CE every 10 years).

Virtual CE

Three RCTs compared NBI in all cases with HD-WLE for the detection of neoplasia in long-standing IBD. Regardless of the generation of the NBI device and the level of definition of colonoscopies used, virtual CE did not significantly increase the detection rate of neoplastic lesions as compared with WLE [77–79]. However, virtual CE with targeted biopsies alone yielded neoplasia detection rates comparable to WLE with targeted and random four-quadrant biopsies (mean number of biopsies per patient: 0.5–3.5 in NBI with targeted biopsies only, and 24.6–38.3 in WLE with targeted and random biopsies).

Two RCTs compared a HD-NBI system with high definition dye-based CE, both without nontargeted biopsies, for the detection of neoplasia in long-standing UC. The first, single-center, crossover RCT comparing neoplasia miss rates with HD-NBI and high definition dye-based CE [80], showed a considerably higher miss rate of neoplastic lesions with HD-NBI as compared with high definition dye-based CE (31.8% and 13.6%, respectively). However, this study was not adequately powered to show a statistical significance. The second was a recent multicenter RCT that compared HD-CE with HD-NBI in 131 patients with UC in a 1:1 randomization [81]. Mean numbers of neoplastic lesions per colonoscopy were 0.47 for CE and 0.32 for NBI (P = 0.992). The neoplasia detection rate did not differ significantly between CE and NBI (21.2% vs. 21.5%, respectively). The per-lesion neoplasia detection was 17.4% for CE and 16.3% for NBI (P = 0.793) and the total procedural time was on average 7 minutes shorter in the NBI group.

One study compared I-SCAN as virtual CE with HD-WLE and dye-based HD-CE. There was no significant difference between three groups of patients with neoplasia detection (15.5%, 25.5%, and 24.4% respectively). Although 10% noninferiority was just passed statistically, caution should be exercised as the difference might still be clinically relevant [74]. A recent meta-analysis has highlighted the potential role of virtual CE for dysplasia detection in IBD. For the comparison of NBI versus WLE, 4 studies with 305 patients were included. The analysis showed no differences in per-patient neoplasia detection (OR 0.97, 95% CI 0.62–1.53) and per-neoplastic lesion detection (OR 0.94, 95% CI 0.63–1.4) [82].

Two studies (one of them an RCT) compared HD-WLE with AFI for the detection of colorectal neoplasia in IBD [79, 83]. A pilot study [83] showed that protruding lesions with a low AFI signal were significantly more likely to be neoplastic than lesions with a high AFI signal (45.0% vs. 13.3%, respectively; P = 0.043). In the RCT, the miss rate for neoplastic lesions was statistically significantly lower with AFI compared with HD-WLE (0% vs. 50%, P = 0.036) [79]. It should be noted that inadequate bowel preparation and active inflammation interrupt tissue AFI, resulting in discoloration on AFI and resembling neoplasia. Another recent RCT confirmed that AFI did not meet criteria for proceeding to a large noninferiority trial and that the existing AFI imaging technology should not be further investigated as an alternative dysplasia surveillance method [84].

Details of the abovementioned studies are available in Table 11s.

Role of biopsies

A limited diagnostic yield of four-quadrant biopsies in comparison to targeted biopsies has already been shown in the previous Guideline. A pooled sensitivity for the detection of neoplasia with CE-targeted biopsies only was 86% (range 71%–100%) [37, 62, 63, 65, 66, 85–87]. The median numbers of targeted and targeted plus random biopsies were 1.3 (range 0.28–14.2) and 34.3 (range 7.0–42.2), respectively. Therefore, the number of biopsies needed during dye-based CE surveillance of long-standing colitis can be significantly reduced if targeted biopsies are taken. The yield and clinical impact of random biopsies were also assessed in a retrospective analysis of 1010 colonoscopies [88]. Overall, 11,722 random biopsies (median 29) were taken in 466 surveillance colonoscopies. Neopla-
Neoplastic versus non-neoplastic lesions in IBD

RECOMMENDATION

2014 statement:
ESGE recommends taking biopsies from flat mucosa surrounding neoplastic lesions and taking biopsies from or resecting all suspicious lesions identified at neoplasia surveillance in long-standing colitis, because there is no evidence that nonmagnified conventional or virtual chromoendoscopy can reliably differentiate between colitis-associated and sporadic neoplasia or between neoplastic and non-neoplastic lesions (strong recommendation, low to moderate quality evidence).

2019 statement:
ESGE recommends using advanced imaging to assess the borders of lesions in previously colitic mucosa, to assess resectability. If optical diagnosis is used for lesion characterization of visible lesions, ESGE recommends that the suspicion of neoplasia should be confirmed by classical histology in the case of colitis surveillance. Strong recommendation, low quality evidence.

Lesions can be well delineated with high definition endoscopes and advanced imaging techniques. In an RCT comparing dye-based HD-CE with HD-NBI, no dysplasia was found in biopsies taken next to a visible lesion, even when the lesion was flat [81]. This means that if lesions can be well delineated, then resectability can be defined. However the proportion of neoplasia per suspicious lesion detected during colitis surveillance is in general rather low, at around 15% [70,81]. This means that the majority of lesions found are regenerative changes and non-neoplastic. Especially when such lesions are larger, resection may harbor unnecessary risks. The question therefore arises whether optical diagnosis could be used to differentiate neoplastic from non-neoplastic lesions.

Modified pit pattern classifications have been used in three dye-based CE studies to differentiate between neoplastic and non-neoplastic lesions in long-standing IBD [37,62,65], showing high sensitivity and specificity (93% – 100% and 88% – 97%, respectively). Kawasaki et al. evaluated the efficacy of the Japanese magnifying colonoscopy classification (Japan NBI Expert Team [JNET]) for UC-associated neoplasia [92]. Lesions of JNET types IIA, IIB, and III correlated with the histopathological findings of low grade dysplasia (LGD), high grade dysplasia (HGD)/superficially submucosally invasive cancer, and massively submucosally invasive (mSM) carcinoma, respectively. Lesions of Kudo types III/IV, VI low irregularity, and VI high irregularity/ VN, by pit pattern classification, correlated with the histopathological findings of LGD/HGD, HGD, and mSM carcinoma, respectively. One more recent study evaluated the endoscopic features of HGD in 62 patients with UC [93]. HGD imaged with CE and magnifying endoscopy was frequently associated with a flat/superficial elevated area and red color. However, the use of magnifying endoscopy is still not widespread, and total frequency of detection of HGD by magnifying endoscopy is still low. The additional value of virtual CE is based on the fact that it is time-saving (7 minutes less on average than dye-based CE [81]) and may facilitate surveillance in cases of poorer bowel preparation.

Table 12s.

Conclusions: detection of neoplasia in IBD

In conclusion, the literature on advanced imaging in the detection of colitis-associated neoplasia is large but also heterogeneous as illustrated by the several meta-analyses. Although several meta-analyses have been performed on the same literature and sometimes seem to contradict each other, it seems reasonable to accept the additional value of dye-based CE. Recent evidence with HD endoscopes point to the fact that virtual chromoendoscopy also may be equally effective. Although the Spanish real-life study [70] did not show a clear difference in dysplasia detection between expert and nonexpert (18.5% vs. 13.1%, P = 0.20) and did not show a significant learning curve for CE, it is conceivable that lesion recognition by virtual CE is facilitated by previous dye-based CE. In fact, all investigators involved in the virtual CE trials had previous experience with dye-based CE. In standard risk patients, the evidence clearly points to abandoning nontargeted random biopsies. The additional value of using virtual CE lies in the fact that it is time-saving (7 minutes less on average than dye-based CE [81]) and may facilitate surveillance in cases of poorer bowel preparation.

Neoplasia was detected in 88 colonoscopies: in 75 (85%) by targeted biopsies, in 8 (9.1%) by both targeted and random biopsies, and in 5 (5.7%) by random biopsies in 4 patients (7.5% of 53 with detected neoplasia). In 94% of colonoscopies, neoplasia was macroscopically visible. An RCT comparing the rates of neoplasia detection by targeted versus random biopsies in 246 patients with UC found the mean number of biopsies containing neoplastic tissue per colonoscopy to be 0.211 (24 of 114) in the target group and 0.168 (18 of 107) in the random group. Neoplasia was detected in 11.4% of patients in the target group and 9.3% of patients in the random group (P = 0.617). Another, nonrandomized study evaluating different surveillance strategies in 454 IBD patients showed a neoplasia detection rate of 8.2% in the random biopsy group compared to 19.1% in the targeted biopsy group. Recently, a study with 1000 colonoscopies showed neoplasia in 82 patients diagnosed by targeted biopsies or removed lesions. Dysplasia was detected by random biopsies in 7 patients and in 12 additional patients by random biopsies only. The yield of neoplasia by random biopsies only was 0.2% per-biopsy, 1.2% per-colonoscopy and 12.8% per-patient with neoplasia. Dysplasia detected by random biopsies was associated with a personal history of neoplasia, a tubular appearing colon, or the presence of primary sclerosing cholangitis. It may therefore be careful and advisable to combine random biopsies with dye-based or virtual CE-targeted biopsies in these high-risk patients. In addition, since it may be difficult to locate again small lesions with dysplasia, it may be advisable in the case of lesions <10 mm to resect the lesion entirely to facilitate patient management.

Details of the abovementioned studies are available in Table 12.
procedure times were on average 9–11 minutes longer. Recently, a Spanish multicenter trial showed that predictive factors for neoplasia for dye-based CE are Kudo pit pattern III-V, sessile morphology, loss of innominate lines, and location in the right colon [70].

Previous studies evaluating the role of nonmagnified NBI in differentiating neoplastic and non-neoplastic lesions in patients with long-standing colitis suggested that a tortuous pit pattern and a high vascular pattern intensity may help to distinguish neoplastic and non-neoplastic lesions in longstanding IBD [94, 95]. However, in two RCTS, the sensitivity and specificity of NBI in predicting histology were insufficient [79, 96]. A more recent multicenter interobserver study [97] showed median sensitivity, specificity, negative predictive value, and positive predictive value for diagnosing neoplasia, based on the presence of pit pattern other than I or II, of 77%, 68%, 88%, and 46%, respectively. Diagnostic accuracy was significantly higher when a diagnosis was made with a high level of confidence (77% vs. 21%, P<0.001). The agreement for differentiation between non-neoplastic patterns (I, II) and neoplastic patterns (III, IIIS, IV, or V) was moderate and significantly better for NBI in comparison with HD-CE (κ = 0.653 vs. 0.495, P<0.001). Another multicenter RCT compared AFI with CE for dysplasia detection in 210 patients with long-standing UC [98]. Overall sensitivity for real-time prediction of dysplasia was 76.9% for endoscopic trimodal imaging (ETMI; namely, AFI, NBE, and WLE) and 81.6% for CE. Overall negative predictive values were 96.9% for ETMI and 94.7% for CE. A total of 205 lesions in UC were analyzed with virtual CE (flexible spectral imaging color enhancement [FICE]) in another study, by Cassinotti et al. [99]. Sensitivity, specificity, positive and negative likelihood ratios with the Kudo classification were 91%, 76%, 3.8, and 0.12, respectively. Recently Aladrén et al. aimed to analyze results of a CE screening program in Spain and to assess the possibility of identifying low risk dysplastic lesions by their endoscopic appearance, in order to avoid histological analysis [100]. Correlation between dysplasia and Kudo pit pattern predictors of dysplasia (Kudo ≥III) was low while Kudo I and II lesions were correctly identified with a high negative predictive value of 92%, even by nonexperts. Recently a group of international experts has developed and validated a new classification, the Frankfurt Advanced Chromoendooscopic IBD Lesions system (FACILE), using images from all endoscopic platforms, that might improve performance in both trainees and experienced operators. The four characteristics that predicted neoplastic lesions were morphology of nonpolypoid/polypoid lesion, irregular surface pattern, vessel architecture, and signs of inflammation within the lesion, without using Kudo pit pattern [101].

Details of most of the abovementioned studies are available in Table 13s.

Based on these studies we can say that to a certain extent optical diagnosis may help to identify typically non-neoplastic lesions with type I or II pit pattern, but that the overall diagnostic accuracy, even in expert hands, is insufficient. Resection of small lesions ≤10 mm with a neoplastic pit pattern is probably safe and may be more practical for determining patient management in the case that neoplasia is found. However in larger lesions, with sessile morphology or in the right colon [70], a biopsy should always be taken to confirm or rule out dysplasia.

### Differentiation between neoplastic and non-neoplastic small colorectal polyps

**RECOMMENDATION**

**2014 statement:**

ESGE suggests that virtual chromoendoscopy (NBI, FICE, i-SCAN) and conventional [dyebased] chromoendoscopy can be used, under strictly controlled conditions, for real-time optical diagnosis of diminutive (≤5 mm) colorectal polyps to replace histopathological diagnosis. The optical diagnosis has to be reported using validated scales, must be adequately photodocumented, and can be performed only by experienced endoscopists who are adequately trained and audited (weak recommendation, high quality evidence).

**2019 statement:**

ESGE suggests that virtual chromoendoscopy and dye-based chromoendoscopy can be used, under strictly controlled conditions, for real-time optical diagnosis of diminutive (≤5 mm) colorectal polyps to replace histopathological diagnosis. The optical diagnosis should be reported using a validated scale, must be adequately photodocumented, and can be performed only by experienced endoscopists who are adequately trained, as defined in the ESGE curriculum, and audited. Weak recommendation, high quality evidence.

The vast majority of polyps detected during colonoscopy are diminutive (1–5 mm) or small (6–9 mm) in size. Diminutive polyps represent approximately 60% of all polyps detected and the risk of advanced pathology or cancer incurred by these lesions is very low [102 – 104]. However, based on current management protocols, all removed polyps, including diminutive polyps, are submitted for histological analysis. This is expensive and generates a large burden of work for pathologists and histopathology departments. Instead of sending diminutive polyps for histological evaluation, a real-time optical diagnosis by the endoscopist would allow diminutive polyps to be discarded after resection, and non-neoplastic polyps located in the rectum and sigmoid to be left in situ. Furthermore, optical diagnosis could be used to determine the interval for the next surveillance colonoscopy. The primary goal of this strategy is to reduce the number of polyps submitted for histopathological evaluation, which may lead to cost savings.

The optical diagnosis strategy also raises several concerns. First, when diminutive polyps are discarded, advanced histological features (high grade dysplasia, tubulovillous or villous morphology) or invasive growth, i.e., a cancer, are not diagnosed as such. This could lead to a setting of suboptimal
treatment and/or inappropriate surveillance intervals. However, risk estimates for advanced pathology within diminutive polyps are low, ranging from 0.1% to 12%, with most estimates at the lower end of this range [105–134] (Table 14s). The rate of cancer in diminutive polyps is even lower, although not completely negligible, ranging from 0% to 0.6%, with most estimates again at the lower end of the range. To further reduce the risk of missing cancer, it is recommended that an optical diagnosis should be avoided in suspicious lesions (e.g. depressed lesions, Paris classification 0-IIc) [135]. The question of whether undiagnosed advanced histological features within diminutive polyps would lead to inappropriate surveillance recommendations was recently addressed in a large study [103]. In this study, data of 12 cohorts (5 FIT cohorts and 7 colonoscopy screening cohorts) were combined, resulting in a total cohort of 64,344 individuals with 51,510 diminutive polyps. Advanced histological features were observed in 5.6% and cancer in 0.07% of all diminutive polyps. The risk of finding metachronous advanced neoplasia did not significantly differ between patients with 1 or 2 nonadvanced diminutive or small adenomas (low-risk patients) compared with patients with diminutive polyps with advanced histological features detected at baseline colonoscopy. This indicates that diminutive polyps with advanced histological features do not increase the risk for metachronous advanced neoplasia and therefore seem not to interfere with a correct surveillance recommendation.

A second concern is that an incorrect optical diagnosis could result in a patient being incorrectly considered at low risk for metachronous advanced neoplasia and/or that neoplastic lesions in the rectosigmoid are left in situ. For this reason, the American Society for Gastrointestinal Endoscopy (ASGE) published the Preservation and Incorporation of Valuable Endoscopic Imagenation (PIVI) document in which they attempted to set standards against which a technology should be assessed in order to be deemed suitable for use. A policy of resect and discard should have ≥90% agreement in assignment of post-polypectomy surveillance intervals when compared with decisions based on pathology assessment, and a policy of leaving suspected non-neoplastic polyps in place should have a ≥90% negative predictive value when used with high confidence [136]. A meta-analysis published in 2015 [137], including 20 NBI studies [138–157], 7 I-SCAN studies [155, 158–163] and 8 FICE studies [164–171], all in vivo and published between 2008 and 2014, showed that the pooled NPV of NBI for adenomatous polyp histology was 91% (95% CI 88%–94%). The agreement in assignment of post-polypectomy surveillance intervals with NBI was 89% (95% CI 85%–93%). Importantly, subgroup analysis indicated that the pooled NPV and the surveillance agreement was only greater than 90% for academic medical centers, for experts, and when the optical assessment was made with high confidence. Comparable results were observed for I-SCAN. For FICE the pooled NPV in this meta-analysis was 80% (95% CI 76%–85%). Dye-based CE shows similar accuracy in differentiating between neoplastic and non-neoplastic polyps, but because of inconvenience and costs associated with the use of dyes it is unlikely that this technique will be adopted in routine clinical practice [164, 166]. From 2015 onwards, real-time differentiation studies, performed in academic centers as well as in community hospitals, have shown conflicting results in achieving the above-mentioned PIVI thresholds [125, 172–179]. This variability in performance may be explained by a lack of rigorous training and/or performance measurement. However, in those studies in which the endoscopists were adequately trained prior to the study, PIVI thresholds were also not always met [125, 174, 179]. In conclusion, performance levels of endoscopists in correctly predicting histology of diminutive polyps remain highly variable, underlining the necessity of a training, auditing, and performance monitoring system when an optical diagnosis strategy is implemented. The possible effect on optical diagnosis of the use of artificial intelligence (AI) in the future is also unclear at this stage (see section on Role of artificial intelligence). Details of the above-mentioned studies are available in Table 15s.

During real-time optical diagnosis, validated optical diagnostic scales, such as the widely used NBI International Colorectal Endoscopic (NICE) classification or the Workgroup serrAted polypS and Polyposis (WASP) classification (which also includes sessile serrated lesions [SSLS]) should be used to improve diagnostic accuracy [145, 174, 180]. No universal training system for differentiation between neoplastic and non-neoplastic colorectal polyps has been established yet. Several teaching modules, mostly computer-based, have been studied and some of them are showing promising results with respect to improving interobserver agreement; however in a substantial number of studies the interobserver agreement was still moderate after training [180–188] (Table 16s).

There are currently no data to suggest what kind of documentation is needed for implementation of an optical diagnosis strategy. As in this situation an endoscopic picture, rather than a histology slide, becomes the record of a diminutive polyp, it seems logical that those images are stored. At least one or two images must be stored as evidence of adenoma detection and also for review of the optical diagnosis [136]. However, this strategy poses significant challenges at present, especially with regard to logistics and the available disk space on servers in endoscopy units.

Implementation of an optical diagnosis strategy would be cost-effective, with good evidence from large modeling studies to support this [157, 170, 189–193]. However, concerns associated with the data used for model analysis include: (i) the different CRC screening programs used in these models may not be simply extrapolated to the various screening programs in use in Europe; (ii) the assumptions are derived from studies that have mainly been performed by experts; and (iii) the costs for implementation of the resect-and-discard policy (training for and photodocumentation of real-time diagnosis) are not included. It is therefore unclear whether the results of these modeling studies can be reproduced in real-life daily practice, and this should be further investigated in a real-life (multicenter) setting.
Role of advanced imaging in treatment of colorectal neoplasia
Prediction of deep submucosal invasion

RECOMMENDATION
2014 statement: ESGE suggests the use of conventional or virtual (NBI) magnified chromoendoscopy to predict the risk of invasive cancer and deep submucosal invasion in lesions such as those with a depressed component (0-Ic according to the Paris classification) or nongranular or mixed-type laterally spreading tumors (weak recommendation, moderate quality evidence).

2019 statement: ESGE recommends the use of high definition white light endoscopy in combination with (virtual) chromoendoscopy to predict the presence and depth of any submucosal invasion in nonpedunculated colorectal polyps prior to any treatment.

Strong recommendation, moderate quality evidence.

When endoscopic resection is considered for colonic lesions, it is important to assess the lesion accurately and attempt to predict the presence and depth of submucosal invasion, as this will aid in determining the correct treatment strategy (piecemeal endoscopic resection, e.g., endoscopic mucosal resection [EMR]; en bloc endoscopic resection, e.g., endoscopic submucosal dissection [ESD] or use of full thickness resection device [FTRD], or surgery). White light characterization and virtual and dye-based CE with and without magnification help to predict the presence and depth of submucosal invasion.

Morphology, size, location, and recognition of gross morphological features are the first steps in the characterization of colonic lesions with WLE, and may help to raise suspicion of malignancy. Submucosal invasion has been shown elsewhere to be more frequent in certain morphologies (laterally spreading tumor of nongranular type [LST-NG] pseudodepressed lesions, and also sessile polyps), increased size, and rectal location [194, 195]. A large prospective study of colonic lesions showed that the risk of ‘covert’ submucosal invasion was predicted by rectosigmoid location (odds ratio 1.87, \(P = 0.01\)), combined Paris classification, surface morphology (odds ratios, 3.96–22.5), and increasing size (odds ratio 1.16/10 mm, \(P = 0.012\)) [196]. In particular, rectosigmoid Paris 0-Is and 0-Ila + Is nongranular lesions had a high risk of submucosal invasion whereas proximally located Paris 0-Is or 0-Ila granular lesions had a very low risk. In addition, the nonlifting sign, chicken skin sign, edge retraction, depressed areas, folds convergence, induration, ulceration, polyp over polyp, redness, tumor fullness, and spontaneous bleeding have been reported to be associated with submucosal invasion, and also in lesions <10 mm, but none of them was definitive [194, 197]. A systematic review and meta-analysis showed that sensitivities of these features for predicting deep submucosal invasion ranged from 18% to 68% and specificities from 80% to 98% [198]. The recognition of demarcated areas (clearly visualized region between two morphological areas of a lesion, e.g., a depression, large nodule, or reddened area) is also a key point in identifying zones that deserve close observation, because they are associated with an increased risk of submucosal invasion [199].

On closer inspection of the target colonic lesion, detection and characterization of a demarcated area where a regular nongranular pit/vascular pattern (e.g., Kudo IV, NICE II, Sano II) becomes disordered (e.g., Kudo V, NICE III, Sano III), often associated with a visible depression (Paris classification 0-Ila + c) due to a fibrotic reaction in the submucosa, is a specific marker of submucosal invasion within colonic lesions.

There are only three prospective studies evaluating in vivo CE without magnification. The OPTICAL study [200] prospectively assessed 343 large nonpedunculated colorectal polyps with NBI without magnification, using the Hiroshima classification. A total of 47 cancers were identified (36 T1 and 11 ≥ T2), of which only 11 contained superficial sm1 invasion (23.4% of all malignant polyps). Sensitivity and specificity for optical diagnosis of T1 CRC were 78.7% (95% CI 64.3%–89.3%) and 94.2% (95% CI 90.9%–96.6%), respectively; corresponding values for optical diagnosis of endoscopically unresectable lesions (i.e., ≥ T1 CRC with deep invasion) were 63.3% (95% CI 43.9%–80.1%) and 99.0% (95% CI 97.1%–100.0%), respectively. Obvious advanced cancers were excluded, but 11 out of 47 were still advanced cancers (7 T2 and 4 T3), which might have increased the sensitivity.

In a Spanish multicenter prospective study including 2123 lesions >10 mm using NBI and without magnification, the NICE classification system identified lesions with deep invasion with sensitivity 58.4% (95% CI 47.5%–68.8%) and specificity 96.4% (95% CI 95.5%–97.2%) [194]. In addition, a conditional inference tree that included all variables found that the NICE classification was the most accurate for identification of lesions with deep invasion (\(P < 0.001\)). However, pedunculated morphology (\(P < 0.007\)), ulceration (\(P = 0.026\)), depressed areas (\(P < 0.001\)), or nodular-mixed type (\(P < 0.001\)) also affected accuracy of identification (► Fig. 1). Therefore, virtual CE without magnification is useful for predicting deep submucosal invasion when a nonpedunculated NICE type 3 polyp is ulcerated and is useful to rule it out when a NICE type 1 or 2 lesion has no depressed area nor nodules. Results were comparable for identifying lesions that were endoscopically not resectable for oncological reasons (with any risk factor for lymph node metastasis). This is consistent with previous Japanese studies showing a higher prevalence of deep submucosal invasion in demarcated areas [199]. Therefore, magnification is especially needed in nonulcerated NICE type 3 lesions or when a demarcated area (nodule, redness, or depression) is present in a NICE type 1 or 2 lesion.

There is only one study assessing the Kudo pit pattern for predicting submucosal invasion without magnification [196]. Sensitivity and specificity of the Kudo pit pattern type V were 40.4% (95% CI 33.3%–47.8%) and 97.5% (95% CI 96.7%–98.1%) in 2106 laterally spreading lesions >20 mm.

In Japan, magnified NBI CE has been shown to have a sensitivity of 77% (95% CI 68%–84%) and a specificity of 98% (95% CI...
95%–99%) in 13 studies using different classification systems [198]. Recently, type 3 JNET classification has shown a sensitivity of 55.4% (95%CI 48.7%–62.1%) and a specificity of 99.8% (95%CI 99.6%–100.0%) in retrospective assessment of 2933 images [201]. Studies with similar results showed that JNET type 2B included a wide variety of colorectal tumors ranging from low grade dysplasia to deep submucosal lesions and therefore the sensitivity of JNET type 3 is low [202–207]. The authors suggest that direct observation of the Kudo pit pattern with crystal violet should be performed in JNET 2B lesions.

The abovementioned systematic review and meta-analysis showed a sensitivity of 81% (95%CI 75%–87%) and a specificity of 95% (95%CI 89%–97%) for magnified CE in 17 studies [198]. All the studies were performed in Asian countries, mainly Japan, and with crystal violet. A retrospective study conducted in Brazil by a single experienced endoscopist included 123 lesions with suspicion of submucosal invasion raised by another endoscopist. Magnifying CE with pit pattern classification had 73.3% sensitivity and 100% specificity [208].

Details of the most important of the abovementioned studies are available in Table 17s.

In summary: WLE may raise suspicion for submucosal invasion; virtual CE without magnification is useful to rule out the presence of deep submucosal invasion when no demarcated area is present; and magnifying CE may allow the differentiation between deep and superficial submucosal invasion in highly suspicious lesions, such as those containing demarcated areas. Based on the recent evidence, a 4-step strategy incorporating the different roles of WLE, nonmagnifying virtual CE, magnifying virtual CE, and magnifying dye-based CE in predicting submucosal invasion has been proposed, but it should first be validated [209]. In the near future, it seems likely that AI, directed to a demarcated area by a human observer, will significantly improve both sensitivity and specificity (see section on Role of artificial intelligence).

Defining the borders of colorectal lesions

RECOMMENDATION
2014 and 2019 statement:
ESGE recommends the use of virtual or conventional [dye-based] chromoendoscopy to define the margins of large nonpolypoid or otherwise indistinct lesions before or during endoscopic resection.
Strong recommendation, very low quality evidence.

No new evidence has become available regarding this statement. Because of the better contrast, the entire extent of the lesion can be better appreciated with additional imaging techniques to safeguard a complete resection of a lesion. Especially in IBD-related neoplasia, demarcation of a lesion can be challenging and is facilitated by CE.
Follow-up after endoscopic resection of lesions

**RECOMMENDATIONS**

2014 statement: 
ESGE recommends the use of virtual or conventional chro-moendoscopy in addition to white light endoscopy for the detection of residual neoplasia at a piecemeal polypectomy scar site (strong recommendation, low quality evidence).

2019 statements: 
ESGE recommends the use of virtual or dye-based chro-moendoscopy in addition to white-light endoscopy for the detection of residual neoplasia at a piecemeal polypectomy scar site. 
Strong recommendation, moderate quality evidence.

ESGE suggests that routine biopsy of post-polypectomy scars can be abandoned providing that a standardized imaging protocol with virtual chro-moendoscopy is used by a sufficiently trained endoscopist. 
Weak recommendation, moderate quality evidence.

Endoscopic piecemeal polypectomy has emerged as a safe and effective method of removing large sessile or nonpolypoid colorectal lesions. However, because of a relatively high rate of adenoma recurrence, estimated at 15%–30%, [210,211], it is recommended to perform a surveillance colonoscopy at 4–6 months after endoscopic resection [212,213].

It has been shown that using HD-WLE alone allows the identification of 69% to 83% of recurrences revealed by performing targeted and random biopsies [141,214]. Recent studies have provided new evidence for the efficacy of advanced endoscopic imaging in the detection of post-polypectomy/post-EMR scars and residual/recurrent colorectal neoplasia. A prospective single-center study, which analyzed 183 scars after a median of 3.9 months from the endoscopic polypectomy, showed a significantly higher sensitivity for endoscopic residual neoplasia detection for a combination of HD-WLE and NBI compared with HD-WLE alone (93.3% vs. 66.7%). The NPV for the combination of HD-WLE and NBI was 98.6% (95%CI 95.1%–99.8%) [215]. Another prospective multicenter study, which evaluated 255 colorectal scars after a median of 7 months following a colorectal piecemeal EMR, showed a NPV of 100% (95%CI 98%–100%) and sensitivity of 100% (95%CI 93%–100%) for NBI with near-focus imaging [216]. However, slightly lower values were observed in a study of 112 scars, which showed that the accuracy of NBI for the detection of residual neoplasia at the resection site was 86.8%, compared to 81.6% for WLE and (P=0.15) [217]. This study has however several limitations, including the single operator, high recurrence rates, and non-blinded pathologist. Another study, comparing the combination of HD-WLE and virtual or dye-based CE against histological verification in recurrence assessment, revealed biopsy evidence of residual/recurrent lesions in 16 of 228 macroscopically inconspicuous polypectomy scars (7%) [218]. This study had, however, very high rates of recurrence (31.7%) and used argon plasma coagulation to complete or ascertain completeness of resection in 50% of patients. The high sensitivity and NPV (93%–100%) of HD-WLE combined with virtual CE in identifying residual and/or recurrent colorectal neoplasia justifies abandoning biopsy of macroscopically normal EMR or piecemeal polypectomy scars.

Role of artificial intelligence in detection and characterization of colorectal polyps

**RECOMMENDATION**

2019 statement: 
ESGE suggests the possible incorporation of computer-aided diagnosis (detection and characterization of lesions) into colonoscopy, if acceptable and reproducible accuracy for colorectal neoplasia is demonstrated in high quality multicenter in vivo clinical studies. Possible significant risks with implementation, specifically endoscopist deskilling and over-reliance on artificial intelligence (AI), unrepresentative training datasets, and hacking, need be considered.* 
Weak recommendation, low quality evidence.

Computer-aided diagnosis in medical imaging has been revolutionized by the advent of artificial intelligence (AI) “deep learning” based on neural networks that simulate to some degree the workings of the human brain. It seems likely that such systems will have a major place in clinical practice in the future, with more than 20 systems, in particular in radiology and pathology, having received regulatory approval [219]. Video endoscopy provides a further opportunity for the application of AI systems to support and enhance clinical practice and endoscopist performance. However despite the potential benefits, there are also risks associated with the clinical adoption of AI.

Endoscopist – AI interaction

AI can support clinicians in endoscopy in a number of ways. We consider below two major scenarios for colonoscopy, looking at lesion detection and lesion characterization; however the endoscopist can interact with computer-aided diagnosis systems in different ways. This interaction can be active, where we find a polyp and ask the AI system to confirm our diagnosis as a “second reader,” or passive, where AI is running continuously in the background, for example for polyp detection, providing a “concurrent read” alongside the endoscopist. There may be situations where AI acts completely autonomously to make a decision without any endoscopist input, and it is unknown how the AI output is determined [220] (Fig. 2). An expert group set up by the European Commission has recently proposed that algorithms’ “black boxes” should be deconvoluted before they can be used for patient care [221]. The levels of

* Note: The field of AI is changing very rapidly and it is likely this statement may need to be modified as new data emerge. ESGE plans an addendum to this section of the Guideline in the near future.
endoscopist–AI interaction have similarities to self-driving cars. For example, humans can monitor the environment but can be aided by automated speed control and braking; self-driving may also allow the AI system to monitor the environment, with limited human input, or even to be fully autonomous. However it seems unlikely that fully autonomous “black box” AI will feature widely in medicine [219].

Diagnostic performance of AI in colonic polyp detection

Substantial variation exists among endoscopists in terms of polyp detection and effectiveness in preventing CRC with colonoscopy [4, 11]. This variability has been attributed to many factors, but a significant cause seems to be that potentially detectable polyps are missed [179, 222–225]. The limitations of human visual perception and other human factors, such as fatigue, distraction, and level of alertness during examination, increase such recognition errors, and their mitigation may be the key to improving polyp detection and further reduction in CRC mortality. Computer-aided detection (CAD) could address these limitations [226]. Recent advances in AI, deep learning, and computer vision have shown potential for assisting polyp detection during colonoscopy.

Preliminary studies of deep learning-based CAD systems have reported sensitivities from 70% to 90% and specificities from 60% to 90% for detecting polyps [227–232]. There is insufficient data to establish whether there is effective detection of sessile serrated or relatively flat and depressed lesions (Paris 0-II).

Although CAD could be useful for polyp detection in clinical practice [228], some limitations remain. A major drawback of current CAD systems is the relatively large number of false-positive detections, which could adversely affect the application of CAD in clinical practice. A large rate of false positives is likely to confound the endoscopist’s task of image interpretation and reduce the efficiency of colonoscopy. In addition, endoscopists may lose confidence in CAD as a useful tool. The speed of CAD for image analysis and output presentation may also be an issue. Fast processing times are required for image analysis and on-screen labeling, so that the endoscopist is alerted in real time to the presence of a polyp.

Details of the more important of the abovementioned studies are available in Table 18s.

Diagnostic performance of AI in polyp characterization

AI for characterization of colorectal lesions might have potential advantages in: (i) improving the endoscopist’s learning phase; (ii) predicting neoplastic and non-neoplastic tissue (e.g., to support a resect-and-discard strategy); and (iii) guiding endoscopic therapy (e.g., by prediction of submucosal infiltration). So far, no randomized controlled trials have assessed this rapidly emerging technology.

Specifically, no data are yet available on the effect of AI on the learning curve of endoscopists. Regarding prediction of adenomatous and hyperplastic polyp histology, recent data have highlighted that AI based on deep learning models can accurately predict polyp histology with sensitivities and NPVs exceeding 90% [233, 234]. Similar results have also been shown for AI based on traditional machine learning [235, 236]. AI based on machine learning has also been evaluated for predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer; it was found that it could significantly reduce unnecessary additional surgery [237]. Finally AI based on a deep learning model has been used to assist in diagnosis of submucosal CRC showing an accuracy of 81% [238, 239].

Beyond colonic polyps there may be a role for AI in scoring inflammation in IBD, with preliminary data supporting distinction between Mayo 0–1 levels of inflammation and higher Mayo 2–3 levels (area under receiver operating characteristic [AUROC] 0.98) [240]. In addition, AI may potentially help in au-
tomatically registering quality indicators for colonoscopy (withdrawal time, cecal intubation, bowel preparation).

Details of the most important of the abovementioned studies are available in Table 19a.

The role of add-on standalone systems versus AI that is integrated into commercially available endoscopy systems remains unclear. However either approach seems to have significant potential to enhance practice and facilitate optical diagnosis or resect-and-discard strategies [220].

Risks of AI in clinical practice

Whilst many previous publications have exclusively mentioned the strengths and advantages of the use of AI in medicine, there are potential drawbacks to using AI in colonoscopy. In seven prospective studies on AI in colonoscopy [231, 235, 241–245], none addressed the downsides of AI as one of the main outcome measures, except for assessment of the time required for using AI; results varied from an increase of 35–47 seconds per polyp assessed with AI [235] to no additional withdrawal time [231].

Outside the field of colonoscopy, recent review articles have warned of unintended consequences that possibly arise from the use of AI in health care [219, 246], namely over-reliance on AI, deskilling, biased datasets for machine learning, and the risk of hacking, all of which seem to be applicable to AI in colonoscopy. In the short term, endoscopists’ diagnoses can be affected by incorrect AI predictions. Some previous studies on decision support systems for mammography [247] and electrocardiography [248] demonstrated this negative effect in practice. According to these studies, experienced radiologists and residents, respectively, tended to adopt wrong decisions when they were given an incorrect AI prediction.

The problem of biased data for machine learning should be addressed when AI is widely implemented into colonoscopy practice. Currently, no colonoscopy AI systems have used learning data from different countries, although the status of colonic mucosa, morphologic pattern of polyps, and quality of bowel preparation may differ significantly among countries. Similarly, differences in endoscopic technology among regions of the world (e.g. between the Olympus Lucera Elite and the Exera III) or between endoscopy manufacturers may significantly affect AI performance if the training sets had not included a full range of data. In this regard, international validation should be required before global use of the developed AI. Small, unrepresentative data sets can lead to unintended outcomes, as happened with the IBM Watson for Oncology software [249]. Wide adoption of such data sets in healthcare systems can have far-reaching negative consequences.

The risk of hacking is also an inevitable concern. Deliberate hacking of a computer with AI installed could lead to large-scale harm to patients. For example, use of AI which provides wrong histological predictions because of malware could lead to serious consequences, such as neoplastic polyps being left in situ.

A more specific concern is that endoscopists using CAD are obliged to pay attention to the CAD output at the same time as making their own assessment. Thus the CAD output, especially if it was inaccurate, might distract the endoscopist, leading to missing or mischaracterization of polyps [250]. On the other hand, no serious adverse event such as perforation has been reported that was due to such distraction, according to two prospective studies [235, 244]. Detection algorithms may produce many false positives which require careful mucosal inspection; this can increase the time and mental load when performing colonoscopy, leading to a lessening of concentration.

There is also an assumption that effects of CAD (e.g. improved adenoma detection) will automatically lead to a reduction in missed CRC, because of the association between ADR and post-colonoscopy CRC [11]. However, changes in ADR produced by AI are in effect improvements in detection of polyps within the visual field, and AI cannot detect polyps in non-inspected mucosa. Therefore if improved ADR is in fact a surrogate measure of enhanced mucosal visualization, with better re-inspection of flexures, suctioning and pressing down mucosal folds, factors not changed by application of AI, the link between enhancement of ADR and fewer missed cancers may not hold true.

Although the evidence on the risks of AI for colonoscopy is limited, nevertheless various risks of AI such as prolonged procedure time, over-reliance on AI, and distraction caused by AI, should be considered, and quality assurance measures instituted [251, 252]. Future prospective studies should assess the impact of these downsides of AI in addition to its efficacy.

Disclaimers

The legal disclaimer for ESGE guidelines [10] applies to this Guideline.

The views expressed by J.E. East and M. Iacucci are those of these authors and not necessarily those of the National Health Service (England and Wales), the National Institute for Health Research or the UK Department of Health.

Funding

J.E. East was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, and M. Iacucci receives funding support from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre. R. Bisschops was funded by a grant of the Research Foundation Flanders (FWO). Y. Mori was funded by the Japan Society for the Promotion of Science. E. Coron, H. Neumann, and Y. Hazewinkel received no funding.

Acknowledgments

The authors gratefully thank Prof. Brian P. Saunders, of the Wolfson Unit for Endoscopy, St. Mark’s Hospital, Harrow, UK, and Dr. David Tate, of the University Hospital Ghent, Belgium, for their excellent review of the Guideline.
Competing interests

R. Bisschops has provided consultancy to and received research grants and speaker’s fees from Pentax (2008 to present) and Fujifilm (2015 to present); his department has received research grants and equipment from Pentax and Fujifilm (2015 to present). E. Corone received speaker’s fees or congress invitations from Fujifilm (2016 – 2019), and speaker’s fees from Olympus (2016, 2017). J. East received a speaker’s fee from Falk (January 2018); he has served on a Clinical Advisory Board of Boston Scientific (March 2018 to March 2019). C. Hassan has received research support from Fujifilm (2017 to present); his department has received support from Sonoscape. J. E. van Hooft has received lecture fees from Medtronic (2014–2015) and Cook Medical (2019), and consultancy fees from Boston Scientific (2014–2017); her department has received research grants from Cook Medical (2014–2018) and Abbott (2014–2017). M. Iacucci has received a research grant and consultancy fee from Pentax (2013–2019), and a research grant from Fujifilm (2018–2019); her department has received a research grant from Olympus (2017–2019). M. F. Kamiński has received speaker’s, teaching, and consultancy fees from Olympus (2017 to present) and speaker’s and teaching fees, and a loan of equipment from Fujifilm (2019). H. Neumann has provided consultancy to Fujifilm, Pentax, Motus GI, Boston Scientific, and Cook (2012 to present). M. Pellisé has received speaker’s fees from Casen Recordati (2016–2019), Olympus (2018), and Jansen (2018), consultancy and speaker’s fees from Norgine Iberia (2015–2019), a consultancy fee from GI Apply (2019), and research funding from Fujifilm Spain (2019); her department has received material on loan from Fujifilm Spain (2017 to present) and research grants from Olympus Europe (2005 to present); she is a board member of ES GE and SEED (2016 to present). I. Puig’s department has received loans of equipment to conduct a study from Olympus Europe (2019–2021) and Fujifilm Europe (January 2019–December 2019). Y. Morikawa has provided consultancy to and received a Speaker’s honorarium from Olympus (2017–2019). G. Antonelli, M. Bustamente Balleño, G. Cortas, E. Dekker, V. Hazewinkel, G. Longcroft-Wheaton, and N. Pilonis have no competing interests.

References

[54] Vemulapalli KC, Rex DK. Failure to recognize serrated polyposis syndrome in a cohort with large sessile colorectal polyps. Gastrointest Endosc 2012; 75: 1206–1210


Tsai FC, Strum WB. Prevalence of advanced adenomas in small and diminutive polyps using direct measurement of size. Dig Dis Sci 2011; 56: 2384–2388 Epub 2011 Feb 12


Oka S, Tanaka S, Nakadi K et al. Endoscopic features and management of diminutive colorectal submucosal invasive carcinoma. Dig Endosc 2014; 26: (Suppl. 02): 78–83


Iwai T, Imai K, Hotta K et al. Endoscopic prediction of advanced histology in diminutive and small colorectal polyps. J Gastroenterol Hepatol 2019; 34: 397–403 Epub 2018 Aug 16

Turner KO, Genta RM, Sonnenberg A. Lesions of all types exist in colon polyps of all sizes. Am J Gastroenterol 2018; 113: 303–306 Epub 2017 Dec 12


Denis B, Bottlaender J, Weiss AM et al. Some diminutive colorectal polyps can be removed and discarded without pathological examination. Endoscopy 2011; 43: 81–86 Epub 2010 Nov 24

Graser A, Stieber P, Nagel D et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the...


Ichimasa K, Kudo S, Mori Y et al. Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer. Endoscopy 2018; 50: 230–240


